Literature DB >> 9450915

Toxicologic effects of an oligodeoxynucleotide phosphorothioate and its analogs following intravenous administration in rats.

S Agrawal1, Q Zhao, Z Jiang, C Oliver, H Giles, J Heath, D Serota.   

Abstract

The aim of the present study is to evaluate the in vivo toxicologic effects of a phosphorothioate oligodeoxynucleotide (PS oligo) and three of its analogs [PS oligo containing four methylphosphonate linkages at the 3' and 5'-ends (MBO 1), PS oligo containing four 2'-O-methylribonucleosides at both the 3'- and 5'-ends (MBO 2), and PS oligo containing an 8 bp loop region at the 3'-end (self-stabilized oligo)]. Oligodeoxynucleotides were administrated intravenously to male and female rats at doses of 3, 10, and 30 mg/kg/day for 14 days. Rats were killed on day 15, blood samples were collected for hematology and clinical chemistry determinations, and tissues, including lymph nodes, spleens, livers, and kidneys, were subjected to pathologic examinations. The toxicity profiles of the four oligodeoxynucleotides were very similar, but differed in magnitude. In terms of the severity of the abnormalities caused by the oligodeoxynucleotides, the order was MBO 2 > PS oligo > self-stabilized oligo > MBO 1. Alterations in hematology parameters included thrombocytopenia, anemia, and neutropenia. Abnormalities in clinical chemistry parameters observed with PS oligo or MBO 2 were dose-dependent elevation of liver transaminases and reduction of the levels of alkaline phosphatase, albumin, and total protein. In addition, MBO 2 caused elevation of the total bilirubin level in male rats at the 30 mg/kg dose. No major alterations in hematology or clinical chemistry were observed in rats receiving MBO 1 or self-stabilized oligo. Dose-dependent enlargements of spleen, liver, and kidney were observed, especially in rats receiving PS oligo and MBO 2. Pathologic studies showed a generalized hyperplasia of the reticuloendothelial (RE) system in the tissues examined. Alterations in the spleen were mainly RE cell hyperplasia and hematopoietic cell proliferation. In addition to RE cell hyperplasia, lymph nodes showed necrosis, hepatocytes showed cytologic alterations and necrosis, and kidneys showed renal tubule regeneration. The severity of pathologic changes observed was oligodeoxynucleotide dependent, in the order of MBO 2 > PS oligo > self-stabilized oligo > MBO 1.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9450915     DOI: 10.1089/oli.1.1997.7.575

Source DB:  PubMed          Journal:  Antisense Nucleic Acid Drug Dev        ISSN: 1087-2906


  7 in total

1.  Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1.

Authors:  Sanjay K Pandey; Thurman M Wheeler; Samantha L Justice; Aneeza Kim; Husam S Younis; Danielle Gattis; Dominic Jauvin; Jack Puymirat; Eric E Swayze; Susan M Freier; C Frank Bennett; Charles A Thornton; A Robert MacLeod
Journal:  J Pharmacol Exp Ther       Date:  2015-09-01       Impact factor: 4.030

Review 2.  Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?

Authors:  Elizabeth R Rayburn; Ruiwen Zhang
Journal:  Drug Discov Today       Date:  2008-05-03       Impact factor: 7.851

Review 3.  Involvement of long noncoding RNAs in diseases affecting the central nervous system.

Authors:  Chiara Pastori; Claes Wahlestedt
Journal:  RNA Biol       Date:  2012-06-01       Impact factor: 4.652

4.  Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703.

Authors:  Manuel Schmidt; Nicole Hagner; Alberto Marco; Sven A König-Merediz; Matthias Schroff; Burghardt Wittig
Journal:  Nucleic Acid Ther       Date:  2015-03-31       Impact factor: 5.486

5.  Double-stranded phosphodiester cytosine-guanine oligodeoxynucleotide complexed with calcium phosphate as a potent vaccine adjuvant for activating cellular and Th1-type humoral immunities.

Authors:  Nobutaka Hanagata; Xianglan Li; Min-Hua Chen; Jie Li; Shinya Hattori
Journal:  Int J Nanomedicine       Date:  2017-12-20

Review 6.  CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies.

Authors:  Nobutaka Hanagata
Journal:  Int J Nanomedicine       Date:  2017-01-16

Review 7.  The Evolution of Antisense Oligonucleotide Chemistry-A Personal Journey.

Authors:  Sudhir Agrawal
Journal:  Biomedicines       Date:  2021-05-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.